EGFR+ Lung Cancer

Stage IIIB Unresectable NSCLC After Chemoradiotherapy

Stage IIIA Unresectable NSCLC After Chemoradiotherapy

Pembrolizumab has been granted a priority review designation by the FDA for the treatment of patients with advanced small cell lung cancer whose disease has progressed following ≥2 prior lines of therapy.

Entrectinib has been granted a priority review designation by the FDA as a therapy for&nbsp;select adult and pediatric patients with <em>NTRK</em> fusion&ndash;positive locally advanced or metastatic solid tumors, as well as patients with metastatic <em>ROS1</em>-positive non&ndash;small cell lung cancer, according to Genentech, the developer of the multikinase inhibitor.

Lung Cancer

Edward B. Garon, MD,&nbsp;discussed these data, as well as other trials investigating immunotherapeutic agents for patients with&nbsp;EGFR-mutant non&ndash;small cell lung cancer.

In a presentation during the 2nd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care symposium, Bob T. Li, MD, MPH, explained ctDNA&rsquo;s growing importance in lung cancer, given the disease&rsquo;s challenging prognosis.

Liquid biopsies have evolved beyond finding genotypes and have moved into the cancer detection and monitoring spaces, according to Geoffrey R. Oxnard, MD, medical oncologist at the Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical School.

Rogerio Lilenbaum, MD,&nbsp;highlights the current treatment approaches for patients with <em>EGFR</em>-positive NSCLC and sheds light on the potential for immunotherapy in the space.

Edward B. Garon, MD, discusses data from the IMpower150 trial where patients with <em>EGFR-</em>mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.

A look back at all the&nbsp;FDA news&nbsp;in oncology from the month of&nbsp;January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.

Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.